Document Type
Article
Publication Date
10-9-2022
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a serious clinicopathological condition that is recognized as the most frequent chronic liver disease, affecting 14%-30% of the world’s population. The prevalence of NAFLD has rapidly grown and is correlated with the growth in obesity and type 2 diabetes, among other factors. NAFLD often results in long-term complications including cardiovascular disease, liver cirrhosis, and liver fibrosis. This paper provides an updated overview of NAFLD with a focus on epidemiology, etiology, pathophysiology, screening, complications, and pharmacological therapies to identify effective risk prevention and health promotion.
Recommended Citation
Khan, DO, Adnan; Ross, Heather; Salinas, Natali; Chen, Sarah; Chauhan, Kashyap; Wang, Makala; Yan, BA, Brian; Magagna, John; Beiriger, Jacob; Shah, Yash; Shahzad, Taha; and Halegoua-De Marzio, MD, Dina, "Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD)" (2022). Division of Internal Medicine Faculty Papers & Presentations. Paper 59.
https://jdc.jefferson.edu/internalfp/59
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Language
English
Comments
This article is the author's final published version in, Livers, Volume 2, Issue 4, Pages 264-282.
The published version is available at https://doi.org/10.3390/livers2040022. Copyright © 2022 by the authors.